Addressing the Cold Reality of mRNA Vaccine Stability

Area of Science:

• Pharmaceutical Sciences
• Vaccine Technology
• Biotechnology

Background:

• Messenger RNA (mRNA) vaccines emerged as critical tools during the COVID-19 pandemic.
• Significant challenges in the formulation and long-term storage stability of mRNA vaccine products became evident.
• Existing supply chains faced difficulties in maintaining the required ultra-cold storage conditions for these novel vaccines.

Purpose of the Study:

• To review company proposals for mRNA vaccine storage across the supply chain.
• To analyze the current literature on mRNA vaccine pharmaceutical stability, including stabilization strategies and analytical methods.
• To highlight the need for systematic approaches to understand and improve mRNA vaccine stability.

Main Methods:

• Review of publicly available company information on mRNA vaccine storage proposals.
• Comprehensive literature review of pharmaceutical stability studies for mRNA vaccine candidates.
• Analysis of regulatory guidelines concerning product characterization and storage stability.

Main Results:

• Current approaches to mRNA vaccine storage often rely on ultra-cold conditions, posing logistical challenges.
• Literature reveals ongoing efforts to enhance mRNA vaccine stability through formulation and analytical techniques.
• A lack of systematic investigation into the key physicochemical degradation mechanisms of formulated mRNA vaccines was identified.

Conclusions:

• There is a critical need for the rational design of stabilized mRNA vaccine formulations that can withstand refrigerated or ambient temperatures.
• Addressing mRNA vaccine stability is paramount for ensuring accessibility and effective deployment during current and future health crises.
• Proactive research and development are essential to overcome storage and stability challenges before the next pandemic.